Mangas-Sanchez, CarmenGarriga-Garcia, MariaSerrano-Nieto, Maria JulianaGarcia-Romero, Ruthalvarez-Beltran, MarinaCrehua-Gaudiza, ElenaMunoz-Codoceo, RosanaSuarez-Cortina, LucreciaVicente-Santamaria, SaioaMartinez-Costa, CeciliaDiaz-Martin, Juan JoseBousono-Garcia, CarlosGonzalez-Jimenez, David2025-01-072025-01-072021-12-01https://hdl.handle.net/10668/24437Introduction: In recent years, guidelines for vitamin D supplementation have been updated and prophylactic recommended doses have been increased in patients with cystic fibrosis (CF). Objective: To evaluate safety and efficacy of these new recommendations. Results: Two cohorts of pancreatic insufficient CF patients were compared before (cohort 1: 179 patients) and after (cohort 2: 71 patients) American CF Foundation and European CF Society recommendations were published. Cohort 2 patients received higher Vitamin D doses: 1509 (1306-1711 95% CI) vs 1084 (983-1184 95% CI) IU/Day (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/vitamin Dcystic fibrosismulticenter studyD insufficiencyD deficiencyChildrenCholecalciferolErgocalciferolresearch article34959965open access10.3390/nu131244132072-6643https://www.mdpi.com/2072-6643/13/12/4413/pdf?version=1640221732736882100001